FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Evans Daron						2. Issuer Name and Ticker or Trading Symbol Nile Therapeutics, Inc. [NLTX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O NILE TH		ΓICS, INC.	Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/18/2011								X Officer (give title Other (specify below) below) Chief Financial Officer							
4 WEST 4TH AVENUE, SUITE 400 (Street) SAN MATEO CA 94402					If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State	e) (2	Zip)																
		Ţ	able I - Noi	า-Deriv	ative	Securiti	es Ac	quired, D	ispo	sed o	f, or Ber	eficia	ally Ow	ned					
Date					action Day/Year	Execution () if any	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos		urities Acquired (A) or sed Of (D) (Instr. 3, 4 and 5)			Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) (D)	or F	Price	(Instr. 3 and	(Instr. 3 and 4)				
Common Stoc	ck							+						13,1	13,152		D		
Common Stock														10,200		I		By Spouse	
Common Stock													20	200		I	By Daughter		
Common Stoc	ck												20	200		I	By Son		
			Table II - I					ired, Dis options,					y Owne	ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	4. Trai	nsaction le (Instr.	5. Num Derivat Securit Acquire or Disp	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable Expiration Date (Month/Day/Year)				ying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exercisable		oiration e	Title	Nu	nount or imber of nares		Transacti (Instr. 4)	71(5)			
Stock Option (Right to Buy)	\$2.71							(1)	09/1	17/2017	Commo Stock	1 10	69,797		169,79	97	D		
Stock Option (Right to Buy)	\$2.71							(2)	09/1	17/2017	Commo	2.	39,899		239,899		D		
Stock Option (Right to Buy)	\$0.88							(2)	01/1	15/2019	Commo Stock	1 4	19,020		49,020		D		
Stock Option (Right to Buy)	\$0.89							(3)	06/2	24/2019	Commo	1 8	35,628		85,628		D		
Stock Option (Right to Buy)	\$0.301							(4)	07/0	08/2020	Commo	2	00,000		200,000		D		
Stock Option (Right to Buy)	\$0.37							(4)	07/2	26/2020	Commo	2.	50,000		250,00)0	D		
Stock Option (Right to Buy)	\$0.69	04/18/2011		A		50,000		(2)	04/1	18/2021	Commo Stock	5	50,000	\$0	50,00	0	D		
Warrant (Right to Buy)	\$1.25				\perp			(2)	07/0	07/2014	Commo Stock	1	988		988		D		
Warrant (Right to Buy)	\$1.71							(2)	07/0	07/2014	Commo Stock	1	988		988		D		
Warrant (Right to Buy)	\$2.28				(2) 07/07/2014 Common Stock		1	1,976		1,976		D							

Explanation of Responses:

^{1.} On 9/17/2007, the Reporting Person was granted an option to purchase up to 288,458 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of certain performance milestones as determined by the Compensation Committee of the Board of Directors (the ?Committee?) of the Issuer. On 3/4/2008, the Committee determined that options for the prorated period ending 12/31/2007 would vest in the amount of 76,528 shares, with options to purchase 8,034 shares being forfeited. On January 16, 2009, the Committee determined that options for the period ending 12/31/2008 would vest in the amount of 43,269 shares, with options to purchase 52,884 shares being forfeited. On 1/19/2010, the Committee determined that options for the period ending 12/31/2009 would vest in the amount of 50,000 shares, with options to purchase 46,153 shares being forfeited.

^{2.} Currently exercisable.

- 3. On June 24, 2009, the Reporting Person was granted an option to purchase up to 100,000 shares of common stock of the Issuer, 25,000 of which were immediately exercisable. Vesting of 50,000 of the shares subject to the option was based on the achievement of certain performance milestones (or a pro rata portion thereof for a five-month period of such milestones) following the date of grant. On February 15, 2010, the Reporting Person's right to purchase 42,500 shares of such 50,000-share installment vested based on the achievement of such milestones; the remaining 7,500 shares of such installment were forfeited. Vesting of the final 25,000 shares of the total grant was subject to certain other performance milestones (or a pro rata portion thereof). On January 3, 2011, the Reporting Person's right to purchase 18,128 shares of such final 25,000-share installment vested based on the achievement of such milestones; the remaining 6,872 shares of such installment were forfeited.
- 4. This option vests in twelve equal quarterly installments over three years with the first installment vesting on September 30, 2010.

Remarks:

<u>/s/ Daron Evans</u> <u>04/19/2011</u>

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.